Effect of Indian Gooseberry Extract (AMX160) in Hypercholesterolemia

Last updated: January 9, 2019
Sponsor: Arjuna Natural Limited
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hypercholesterolemia

Treatment

N/A

Clinical Study ID

NCT03479983
AN-06ASE 0717H4-YSM01
  • Ages 18-65
  • All Genders

Study Summary

This study evaluates the efficacy of a fresh fruit extract of Indian Gooseberry (AMX160) for the attenuation of increased blood cholesterol, LDL cholesterol and triglycerides in patients with hypercholesterolemia.

Eligibility Criteria

Inclusion

Inclusion Criteria:

    1. Males and females aged 18 to 65 years with hypercholesterolemia symptoms: bloodTriglycerides, >200 mg/dL, blood cholesterol >200 mg/dL, blood LDL cholesterol >130mg/dL Other requirements for inclusion in the study are:
  1. Moderate-intensity physical activity (less than 150 minutes or less than 75 minutes ofvigorous-intensity physical activity throughout the week) 3. No medication taken formanagement of hypercholesterolemia during last 4 weeks.

  2. Ability to understand and provide signed informed consent. 5. Ability to participate inthe study.

Exclusion

Exclusion Criteria:

  1. Uncontrolled cardiovascular disease or advanced atherosclerosis (e.g. history ofstroke, myocardial infarction, life- threatening arrhythmia, or coronaryrevascularization within the preceding 6 months; unstable angina; congestive heartfailure; known or suspected clinically significant valvular heart disease oruncontrolled hypertension (>160/100 mm of Hg or use of antihypertensive medications,dose of which is not stable in the last one month)

  2. Very high triglyceride levels i.e. > 500 mg/dL

  3. Diabetes (Fasting Blood Sugar>150 mg/dL), using insulin, glitazones , anotherhypoglycemic dose of which is not stable in last one month

  4. Pregnancy, lactation and female patients not using acceptable contraceptive measures (double barrier methods, oral or injectable hormonal contraceptives or surgicalsterilization)

  5. Hepatic impairment (Alanine transaminase or Aspartate transaminase levels > 3.0 mg/dlUpper Limit of Normal (ULN)) or renal impairment (serum creatinine≥ 2.0 mg/dl)

  6. Severe systemic illness and in the opinion of the investigator would be noncompliantwith the visit schedule or study procedures

  7. Known history of hypersensitivity to Indian Gooseberry or any product containingIndian Gooseberry extract

  8. Patients with history of alcohol intake (For females >3 drinks / day or >7 drinks /week. For Males >4 drinks/ day or > 14 drinks / week).

  9. Patients taking any narcotics and prohibited substances.

  10. Serious concurrent illness or malignancy.

  11. Agreements of participation in another clinical trial in the past 3 months

  12. Two of the following risk factors:

  13. Cigarette smoking (Current / Previous smoker < 1 yr)

  14. Hypertension (BP >140/90 mmHg or on antihypertensive medication)

  15. Low HDL cholesterol (<40 mg/dL)

  16. Family history of premature CHD (CHD in male first degree relative <55 years; CHDin female first degree relative <65 years).

Study Design

Total Participants: 132
Study Start date:
June 04, 2018
Estimated Completion Date:
August 31, 2019

Study Description

Phyllanthus emblica L. fruit (Emblica officinalis) has potent antioxidant properties. Animal studies indicate that flavanoids from E. officinalis effectively reduced lipid levels in serum and tissues and had a significant inhibitory effect on hepatic hydroxymethylglutaryl-coenzyme A reductase activity.

The primary aim of this study is to determine whether Phyllanthus emblica L. fruit extract AMX160 is an effective treatment for hypercholesterolemia patients as compared to placebo. The investigators hypothesize that Phyllanthus emblica L. fruit extract AMX160 will significantly lower the total cholesterol as compared to placebo in patients with Hypercholesterolemia. A total of 132 patients including males and females with hypercholesterolemia will be assigned at random to one of the two investigational products. The study is expected to have a treatment duration of 90 ± 10 days and a total duration of 118 days including 14 days of grace period and 14 days of screening period per patient.

Connect with a study center

  • Clinic of General and Invasive Cardiology University Hospital 1, YSMU

    Yerevan, 375025
    Armenia

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.